{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:59:35Z","timestamp":1792202375144,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ijid.2020.12.009","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T17:10:59Z","timestamp":1607533859000},"page":"207-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Pharmacogenetic considerations in the treatment of co-infections with HIV\/AIDS, tuberculosis and malaria in Congolese populations of Central Africa"],"prefix":"10.1016","volume":"104","author":[{"given":"Srinivas Reddy","family":"Pallerla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrel Ornelle","family":"Elion Assiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Thi Kieu","family":"Linh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6105-6388","authenticated-orcid":false,"given":"Frederick Nchang","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5561-2985","authenticated-orcid":false,"given":"Christian G.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaossarath Ad\u00e9djok\u00e8","family":"Fagbemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayola Akim","family":"Adegnika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique Penlap","family":"Beng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Achidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauthier Mesia","family":"Kahunu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0464-1529","authenticated-orcid":false,"given":"Mathew","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Grobusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Ntoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9809-9883","authenticated-orcid":false,"given":"Thirumalaisamy P.","family":"Velavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijid.2020.12.009_bib0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","article-title":"Factors affecting the development of adverse drug reactions (Review article)","volume":"22","author":"Alomar","year":"2014","journal-title":"Saudi Pharm J"},{"issue":"1","key":"10.1016\/j.ijid.2020.12.009_bib0010","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/emph\/eot010","article-title":"African variation at Cytochrome P450 genes: evolutionary aspects and the implications for the treatment of infectious diseases","volume":"2013","author":"Bains","year":"2013","journal-title":"Evol Med Public Health"},{"issue":"2","key":"10.1016\/j.ijid.2020.12.009_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.302","article-title":"Impact of comorbidity on adverse drug reaction profile in a cohort of patients treated with Artemisinin combination therapies for uncomplicated malaria in Nigeria","volume":"5","author":"Bassi","year":"2017","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"10.1016\/j.ijid.2020.12.009_bib0020","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.patbio.2011.07.001","article-title":"Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis","volume":"60","author":"Ben Mahmoud","year":"2012","journal-title":"Pathol Biol (Paris)"},{"issue":"14","key":"10.1016\/j.ijid.2020.12.009_bib0025","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMc1301936","article-title":"Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria","volume":"369","author":"Bennett","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ijid.2020.12.009_bib0030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00228-009-0660-5","article-title":"Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART","volume":"65","author":"Bertrand","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ijid.2020.12.009_bib0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/pgs.11.132","article-title":"Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians","volume":"13","author":"Brown","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.ijid.2020.12.009_bib0040","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/cpt.1403","article-title":"The influence of pharmacogenetic variants in HIV\/Tuberculosis coinfected patients in Uganda in the SOUTH study","volume":"106","author":"Calcagno","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ijid.2020.12.009_bib0045","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/jac\/dkw005","article-title":"Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)","volume":"71","author":"Castillo-Mancilla","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2020.12.009_bib0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00228-004-0871-8","article-title":"CYP2C8 polymorphism frequencies among malaria patients in Zanzibar","volume":"61","author":"Cavaco","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.ijid.2020.12.009_bib0055","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/FPC.0000000000000224","article-title":"tagSNP rs1495741 as a useful molecular marker to predict antituberculosis drug-induced hepatotoxicity","volume":"26","author":"Chamorro","year":"2016","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"10.1016\/j.ijid.2020.12.009_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186200","article-title":"Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients","volume":"12","author":"Chan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2020.12.009_bib0065","first-page":"3","article-title":"Pharmacogenomics for infectious diseases in sub-Saharan Africa: successes and opportunities","volume":"9","author":"Chaudhry","year":"2016","journal-title":"Appl Transl Genom"},{"issue":"9","key":"10.1016\/j.ijid.2020.12.009_bib0070","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/AAC.01833-10","article-title":"The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications","volume":"55","author":"Chigutsa","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2020.12.009_bib0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2217\/pgs.09.142","article-title":"Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique","volume":"11","author":"Ciccacci","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"11","key":"10.1016\/j.ijid.2020.12.009_bib0080","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00228-013-1549-x","article-title":"Association between CYP2B6 polymorphisms and Nevirapine-induced SJS\/TEN: a pharmacogenetics study","volume":"69","author":"Ciccacci","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ijid.2020.12.009_bib0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijantimicag.2015.11.012","article-title":"Efavirenz pharmacogenetics in a cohort of Italian patients","volume":"47","author":"Cusato","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2020.12.009_bib0090","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40360-015-0004-2","article-title":"CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV\/AIDS and TB cohort in Zimbabwe","volume":"16","author":"Dhoro","year":"2015","journal-title":"BMC Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.ijid.2020.12.009_bib0095","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20182105","article-title":"Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis","volume":"39","author":"Du","year":"2019","journal-title":"Biosci Rep"},{"issue":"9","key":"10.1016\/j.ijid.2020.12.009_bib0100","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2217\/pgs.10.94","article-title":"Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients","volume":"11","author":"Elens","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"12","key":"10.1016\/j.ijid.2020.12.009_bib0105","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/tmi.12786","article-title":"Plasmodium falciparum infection in febrile Congolese children: prevalence of clinical malaria 10 years after introduction of artemisinin-combination therapies","volume":"21","author":"Etoka-Beka","year":"2016","journal-title":"Trop Med Int Health"},{"issue":"12","key":"10.1016\/j.ijid.2020.12.009_bib0110","doi-asserted-by":"crossref","first-page":"e4031","DOI":"10.1371\/journal.pone.0004031","article-title":"High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency","volume":"3","author":"Fanello","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ijid.2020.12.009_bib0115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12936-019-2688-z","article-title":"An update on glucose-6-phosphate dehydrogenase deficiency in children from Brazzaville, Republic of Congo","volume":"18","author":"Gampio Gueye","year":"2019","journal-title":"Malar J"},{"issue":"9","key":"10.1016\/j.ijid.2020.12.009_bib0120","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/infdis\/jis508","article-title":"A single-nucleotide polymorphism in CYP2B6 leads to &3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women","volume":"206","author":"Gandhi","year":"2012","journal-title":"J Infect Dis"},{"issue":"7534","key":"10.1016\/j.ijid.2020.12.009_bib0125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature13997","article-title":"The African genome variation project shapes medical genetics in Africa","volume":"517","author":"Gurdasani","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ijid.2020.12.009_bib0130","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":"Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and\/or Nelfinavir: an Adult Aids Clinical Trials Group Study","volume":"192","author":"Haas","year":"2005","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2020.12.009_bib0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/FPC.0b013e32835e95e1","article-title":"The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity","volume":"23","author":"Ho","year":"2013","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.ijid.2020.12.009_bib0140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/FPC.0000000000000034","article-title":"Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202","volume":"24","author":"Johnson","year":"2014","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.ijid.2020.12.009_bib0145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bcp.12620","article-title":"Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer","volume":"80","author":"Kattel","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.ijid.2020.12.009_bib0150","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1089\/aid.2011.0378","article-title":"A population pharmacokinetic-pharmacogenetic analysis of atazanavir","volume":"28","author":"Kile","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"10.1016\/j.ijid.2020.12.009_bib0155","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1478-3231.2011.02697.x","article-title":"TNF-alpha genetic polymorphism -308G\/A and antituberculosis drug-induced hepatitis","volume":"32","author":"Kim","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.ijid.2020.12.009_bib0160","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-2350-10-124","article-title":"Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population","volume":"10","author":"Kudzi","year":"2009","journal-title":"BMC Med Genet"},{"issue":"16","key":"10.1016\/j.ijid.2020.12.009_bib0165","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/QAD.0b013e3283319908","article-title":"CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients","volume":"23","author":"Kwara","year":"2009","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.ijid.2020.12.009_bib0170","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/phar.1388","article-title":"Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance","volume":"34","author":"Kwara","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.ijid.2020.12.009_bib0175","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/FPC.0b013e32834a522e","article-title":"Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine","volume":"21","author":"Lehr","year":"2011","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"10.1016\/j.ijid.2020.12.009_bib0180","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/hmg\/ddq498","article-title":"Global patterns of genetic diversity and signals of natural selection for human ADME genes","volume":"20","author":"Li","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ijid.2020.12.009_bib0185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2016.10.012","article-title":"Health systems in the Republic of Congo: challenges and opportunities for implementing tuberculosis and HIV collaborative service, research, and training activities","volume":"56","author":"Linguissi","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"21","key":"10.1016\/j.ijid.2020.12.009_bib0190","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/ajhp\/59.21.2061","article-title":"Genetic basis of drug metabolism","volume":"59","author":"Ma","year":"2002","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.ijid.2020.12.009_bib0195","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12936-017-1914-9","article-title":"Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women","volume":"16","author":"Mutagonda","year":"2017","journal-title":"Malar J"},{"issue":"12","key":"10.1016\/j.ijid.2020.12.009_bib0200","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1093\/jac\/dku304","article-title":"Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3\u2019 untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study","volume":"69","author":"Nishijima","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ijid.2020.12.009_bib0205","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.clpt.6100122","article-title":"Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa","volume":"82","author":"Parikh","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ijid.2020.12.009_bib0210","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/653427","article-title":"Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency","volume":"51","author":"Park","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2020.12.009_bib0215","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijid.2019.02.025","article-title":"Cytochrome P450 CYP2B6*6 distribution among Congolese individuals with HIV, Tuberculosis and Malaria infection","volume":"82","author":"Peko","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2020.12.009_bib0220","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijid.2019.04.035","article-title":"Distribution of the cytochrome P450 CYP2C8*2 allele in Brazzaville, Republic of Congo","volume":"85","author":"Peko","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2020.12.009_bib0225","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1186\/s12864-016-3078-3","article-title":"Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity","volume":"17","author":"Petros","year":"2016","journal-title":"BMC Genomics"},{"issue":"18","key":"10.1016\/j.ijid.2020.12.009_bib0230","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.286.18.2270","article-title":"Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review","volume":"286","author":"Phillips","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2020.12.009_bib0235","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ebiom.2017.02.017","article-title":"African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development","volume":"17","author":"Rajman","year":"2017","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.ijid.2020.12.009_bib0240","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/tpj.2013.24","article-title":"Pharmacogenomics, ancestry and clinical decision making for global populations","volume":"14","author":"Ramos","year":"2014","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"10.1016\/j.ijid.2020.12.009_bib0245","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3201\/eid0402.980207","article-title":"Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives","volume":"4","author":"Rattan","year":"1998","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2020.12.009_bib0250","article-title":"Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues","volume":"1","author":"Ross","year":"2012","journal-title":"JRSM Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.ijid.2020.12.009_bib0255","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.dmpk.2018.08.004","article-title":"Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation","volume":"33","author":"Saito","year":"2018","journal-title":"Drug Metab Pharmacokinet"},{"issue":"12","key":"10.1016\/j.ijid.2020.12.009_bib0260","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1128\/AAC.00781-10","article-title":"Population pharmacokinetic modeling of the association between 63396C-&T pregnane X receptor polymorphism and unboosted atazanavir clearance","volume":"54","author":"Schipani","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijid.2020.12.009_bib0265","first-page":"895","article-title":"The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces changes in the heme spin state of microsomal cytochrome P-450","volume":"22","author":"Shahi","year":"1990","journal-title":"Biochem Int"},{"issue":"18","key":"10.1016\/j.ijid.2020.12.009_bib0270","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.2217\/pgs.15.144","article-title":"Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis","volume":"16","author":"Shi","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"8089","key":"10.1016\/j.ijid.2020.12.009_bib0275","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(78)92899-4","article-title":"Haemoglobinopathies and G.-6-P.D. deficiency in Laos","volume":"2","author":"Sicard","year":"1978","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ijid.2020.12.009_bib0280","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1086\/592304","article-title":"Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C--&T) with reduced concentrations of unboosted atazanavir","volume":"47","author":"Siccardi","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ijid.2020.12.009_bib0285","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tube.2014.02.003","article-title":"Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity","volume":"94","author":"Singla","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"issue":"1","key":"10.1016\/j.ijid.2020.12.009_bib0290","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bcp.12590","article-title":"Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa","volume":"80","author":"Sinxadi","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.ijid.2020.12.009_bib0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181316","article-title":"Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin","volume":"12","author":"Soeria-Atmadja","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2020.12.009_bib0300","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12936-016-1145-5","article-title":"Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial","volume":"15","author":"St Jean","year":"2016","journal-title":"Malar J"},{"issue":"5930","key":"10.1016\/j.ijid.2020.12.009_bib0305","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1126\/science.1172257","article-title":"The genetic structure and history of Africans and African Americans","volume":"324","author":"Tishkoff","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ijid.2020.12.009_bib0310","first-page":"17","article-title":"HIV transmission and primary drug resistance","volume":"8","author":"Turner","year":"2006","journal-title":"AIDS Rev"},{"issue":"3","key":"10.1016\/j.ijid.2020.12.009_bib0315","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv085","article-title":"Screening for UGT1A1 genotype in study A5257 would have markedly reduced premature discontinuation of atazanavir for hyperbilirubinemia","volume":"2","author":"Vardhanabhuti","year":"2015","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2020.12.009_bib0320","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2020.12.009_bib0325","series-title":"Guidelines for the Treatment of Malaria \u2013 3rd edition","author":"WHO","year":"2015"},{"key":"10.1016\/j.ijid.2020.12.009_bib0330","series-title":"World Malaria Report 2015","author":"WHO","year":"2015"},{"key":"10.1016\/j.ijid.2020.12.009_bib0335","series-title":"Update of Recommendations on First- and Second-Line Antiretroviral Regimens","author":"WHO","year":"2019"},{"issue":"3","key":"10.1016\/j.ijid.2020.12.009_bib0340","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng761","article-title":"Population genetic structure of variable drug response","volume":"29","author":"Wilson","year":"2001","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.ijid.2020.12.009_bib0345","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygeno.2010.07.004","article-title":"Toward a more uniform sampling of human genetic diversity: a survey of worldwide populations by high-density genotyping","volume":"96","author":"Xing","year":"2010","journal-title":"Genomics"},{"issue":"12","key":"10.1016\/j.ijid.2020.12.009_bib0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027810","article-title":"Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients","volume":"6","author":"Yimer","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ijid.2020.12.009_bib0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222033","article-title":"Genetic polymorphisms in PXR and NF-kappaB1 influence susceptibility to anti-tuberculosis drug-induced liver injury","volume":"14","author":"Zhang","year":"2019","journal-title":"PLoS One"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220325327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220325327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:57:26Z","timestamp":1761119846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971220325327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":71,"alternative-id":["S1201971220325327"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2020.12.009","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetic considerations in the treatment of co-infections with HIV\/AIDS, tuberculosis and malaria in Congolese populations of Central Africa","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2020.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}